These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33341070)

  • 1. The potential role of emicizumab prophylaxis in severe von Willebrand disease.
    Barg AA; Avishai E; Budnik I; Brutman TB; Tamarin I; Dardik R; Bashari D; Misgav M; Lubetsky A; Lalezari S; Livnat T; Kenet G
    Blood Cells Mol Dis; 2021 Mar; 87():102530. PubMed ID: 33341070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
    Shanmukhaiah C; Jijina F; Kannan S; Pai NG; Kulkarni B; Khuba SV; Shaikh M; Joshi A; Phatale R; Apte S
    Haemophilia; 2022 Mar; 28(2):286-291. PubMed ID: 35014121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.
    Yaoi H; Shida Y; Ogiwara K; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2022 Sep; 28(5):694-701. PubMed ID: 35478475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
    Thomas VM; Abou-Ismail MY; Lim MY
    Haemophilia; 2022 Jan; 28(1):4-17. PubMed ID: 34820989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
    Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
    J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
    Bravo MI; Raventós A; Pérez A; Costa M; Willis T
    J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
    Takeyama M; Furukawa S; Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Mizumachi K; Noguchi-Sasaki M; Shima M; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1289-1298. PubMed ID: 33641138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab for hemophilia A without inhibitors.
    Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
    Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis.
    Arcudi S; Gualtierotti R; Scalambrino E; Clerici M; Hassan S; Begnozzi V; Boccalandro EA; Novembrino C; Valsecchi C; Palla R; Peyvandi F
    Blood Adv; 2024 Jun; 8(11):2901-2907. PubMed ID: 38531053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.
    Barg AA; Budnik I; Avishai E; Brutman-Barazani T; Bashari D; Misgav M; Lubetsky A; Kuperman AA; Livnat T; Kenet G
    Haemophilia; 2021 May; 27(3):383-391. PubMed ID: 33892524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.